{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:40:54Z","timestamp":1769431254133,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejpb.2018.11.019","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T10:37:31Z","timestamp":1542883051000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products"],"prefix":"10.1016","volume":"134","author":[{"given":"Amitava","family":"Mitra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bostjan","family":"Petek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Bajc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Velagapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Legen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.11.019_b0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK Models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.11.019_b0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1208\/s12248-015-9781-1","article-title":"Application of absorption modeling in rational design of drug product under quality-by-design paradigm","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejpb.2018.11.019_b0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jps.24214","article-title":"A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation","volume":"104","author":"Thiel","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejpb.2018.11.019_b0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/jps.23570","article-title":"The utility of modeling and simulation in drug development and regulatory review","volume":"102","author":"Huang","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2018.11.019_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ejpb.2018.11.019_b0030","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1002\/jps.24474","article-title":"Application of physiologically based absorption modeling for amphetamine salts drug products in generic drug evaluation","volume":"104","author":"Babiskin","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.11.019_b0035","unstructured":"US FDA Guidance to the Industry, Physiological based pharmacokinetic analyses \u2013 format and content. <https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM531207.pdf>."},{"key":"10.1016\/j.ejpb.2018.11.019_b0040","unstructured":"EMA Guideline of the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. <https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-qualification-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf>."},{"key":"10.1016\/j.ejpb.2018.11.019_b0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/psp4.12204","article-title":"Mechanistic oral absorption modeling and simulation for formulation development and bioequivalence evaluation: report of an FDA public workshop","volume":"6","author":"Zhang","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2018.11.019_b0050","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1208\/s12249-014-0075-1","article-title":"Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.ejpb.2018.11.019_b0055","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1208\/s12248-014-9639-y","article-title":"Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin","volume":"16","author":"Parrott","year":"2014","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.ejpb.2018.11.019_b0060","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/jps.24339","article-title":"Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility","volume":"104","author":"Chung","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejpb.2018.11.019_b0065","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.molpharmaceut.6b00424","article-title":"Physiologically based absorption modeling for amorphous solid dispersion formulations","volume":"13","author":"Mitra","year":"2016","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2018.11.019_b0070","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1208\/s12248-017-0075-7","article-title":"Physiologically based pharmacokinetic and absorption modeling for osmotic pump products","volume":"19","author":"Ni","year":"2017","journal-title":"AAPS J."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.11.019_b0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2016.11.063","article-title":"Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities","volume":"519","author":"Hens","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2018.11.019_b0080","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1208\/s12248-016-9952-8","article-title":"A quantitative review and meta-models of the variability and factors affecting oral drug absorption-Part I: gastrointestinal pH","volume":"18","author":"Abuhelwa","year":"2016","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.ejpb.2018.11.019_b0085","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1208\/s12248-016-9953-7","article-title":"A quantitative review and meta-models of the variability and factors affecting oral drug absorption-Part II: gastrointestinal transit time","volume":"18","author":"Abuhelwa","year":"2016","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.ejpb.2018.11.019_b0090","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1007\/s11095-015-1710-6","article-title":"Characterization of contents of distal ileum and cecum to which drugs\/drug products are exposed during bioavailability\/bioequivalence studies in healthy adults","volume":"32","author":"Reppas","year":"2015","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.11.019_b0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2017.10.015","article-title":"Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: the impact of prandial state","volume":"534","author":"Karatza","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2018.11.019_b0100","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1021\/acs.molpharmaceut.6b01129","article-title":"Evaluation of dissolution in the lower intestine and its impact on the absorption process of high dose low solubility drugs","volume":"14","author":"Georgaka","year":"2017","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.ejpb.2018.11.019_b0105","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/acs.molpharmaceut.6b00497","article-title":"Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for Lesinurad immediate release tablets","volume":"13","author":"Pepin","year":"2016","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2018.11.019_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12249-014-0194-8","article-title":"Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets","volume":"16","author":"Mitra","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2018.11.019_b0115","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2018.11.019_b0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2005.08.018","article-title":"Impact of the intragastric location of extended release tablets on food interactions","volume":"108","author":"Weitschies","year":"2005","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118312876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118312876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T16:37:36Z","timestamp":1557333456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118312876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"alternative-id":["S0939641118312876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.11.019","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}